<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794503</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2022-1201</org_study_id>
    <nct_id>NCT05794503</nct_id>
  </id_info>
  <brief_title>Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex</brief_title>
  <official_title>Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to be a single-site, prospective, randomized, controlled study that&#xD;
      intends to enroll a total of 230 patients undergoing laparoscopic cholecystectomy at Parkland&#xD;
      Hospital. Patients will be randomized to receive either neostigmine or sugammadex for&#xD;
      reversal of rocuronium-induced neuromuscular blockade. A standardized anesthetic protocol&#xD;
      that is usual and customary for the type of operation the patient is having will be provided&#xD;
      to the anesthesia teams of enrolled subjects. The remainder of the anesthetic care of the&#xD;
      subject will not deviate from the standard of care. To account for protocol deviations and&#xD;
      patient dropout, up to 250 randomization envelopes will be made and enrollment will continue&#xD;
      until there are 230 completed enrollments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      To determine the incidence of postoperative urinary retention after reversal of&#xD;
      rocuronium-induced neuromuscular blockade by neostigmine versus sugammadex in patients&#xD;
      undergoing laparoscopic cholecystectomy.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Subjects who are reversed with sugammadex will have less postoperative urinary retention&#xD;
      compared to subjects who are reversed with neostigmine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single site, randomized, controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rates of postoperative urinary retention (POUR) of sugammadex and neostigmine groups.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Urinary Retention Postoperative</condition>
  <condition>Laparoscopic Cholecystectomy</condition>
  <condition>Neuromuscular Blockade</condition>
  <condition>Sugammadex</condition>
  <condition>Neostigmine</condition>
  <condition>Neuromuscular Blocking Agents</condition>
  <condition>Physiological Effects of Drugs</condition>
  <arm_group>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One type of Neuromuscular Blockade Reversal Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One type of Neuromuscular Blockade Reversal Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.</description>
    <arm_group_label>Neostigmine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex</description>
    <arm_group_label>Sugammadex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years old&#xD;
&#xD;
          -  Undergoing laparoscopic cholecystectomy&#xD;
&#xD;
          -  Anticipated surgical duration &lt;2 hours&#xD;
&#xD;
          -  ASA physical status classification 1-3&#xD;
&#xD;
          -  Willing and able to consent in English or Spanish&#xD;
&#xD;
          -  No personal history of neuromuscular disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preoperative urinary catheter&#xD;
&#xD;
          -  History of problems with urination&#xD;
&#xD;
          -  Current use of anticholinergic medications (e.g., antihistamines, phenothiazines,&#xD;
             antidepressants, antipsychotics)&#xD;
&#xD;
          -  Current UTI or urogenital problem (incontinence, known bladder retention, prostate&#xD;
             hypertrophy)&#xD;
&#xD;
          -  Planned intraoperative insertion of a urinary catheter&#xD;
&#xD;
          -  ESRD (GRF &lt;30 mL/min)&#xD;
&#xD;
          -  ESLD (AST or ALT &gt; 3x reference range)&#xD;
&#xD;
          -  Planned postoperative intubation/ventilation or admission to ICU&#xD;
&#xD;
          -  Allergy to sugammadex, neostigmine, glycopyrrolate, or rocuronium&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  &quot;Stat&quot; (emergent) cases&#xD;
&#xD;
          -  Known or suspected neurological condition (e.g., Alzheimer's, h/o of stroke, multiple&#xD;
             sclerosis, Parkinson's)&#xD;
&#xD;
          -  Patients on toremifene (a selective estrogen receptor modulator)&#xD;
&#xD;
          -  Women on oral contraceptives who do not wish to use a non-hormonal method of&#xD;
             contraception for 7 days following surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tiffany Moon, MD</last_name>
    <phone>(469) 419-5790</phone>
    <email>tiffany.moon@utsouthwestern.edu</email>
  </overall_contact>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>April 19, 2023</last_update_submitted>
  <last_update_submitted_qc>April 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Tiffany B Moon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

